Indication

As monotherapy is indicated in multiple myeloma (MM) for the maintenance treatment of adult patients with newly diagnosed MM who have undergone autologous stem cell transplantation (ASCT).

Medicine details

Medicine name:
lenalidomide (Revlimid)
SMC ID:
SMC2289
Pharmaceutical company
Celgene Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
12 October 2020
SMC meeting date:
01 September 2020
Patient group submission deadline:
06 July 2020